Lv4
590 积分 2023-04-23 加入
Pan-cancer oncogenic properties and therapeutic potential of SF3B4
1天前
已完结
Anaphylaxis to Penicillin: Harvesting Insights from the Food and Drug Administration's Adverse Event Reporting System
1天前
求助中
"Significant Activity" for ADC in Ovarian Cancer
12天前
已完结
Toxicité cornéenne au mirvétuximab soravtansine : à propos d’un cas
12天前
已关闭
Mirvetuximab Soravtansine: First Approval
12天前
已完结
The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis
12天前
已完结
Mirvetuximab Soravtansine Shines Post-PARP Inhibitor Progression: Promising Insights from the PICCOLO Trial
13天前
已关闭
Ovarian Cancer Therapy
13天前
已完结
Clinical pharmacologic considerations for antibody drug conjugates in gynecologic cancers
13天前
已完结
Arthritis-Related Adverse Reactions of Dupilumab in Treatment of Chronic Rhinosinusitis
13天前
已完结
皖公网安备34019202002308
